BIRC5 and neoplasm: Physiologically expressed by proliferating cells during embryonal development and active in non-neoplastic adult thymic and placenta tissue only, survivin meets a central criterion for targeted tumour therapies as it is upregulated and overexpressed by most malignancies (Kanwar et al. 2013).